
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics has demonstrated a positive trend in utilization growth, averaging approximately 6.1% per quarter over the past six quarters, indicating increasing adoption of its surgical robotics systems. The company's strategic decision to manage operating expenses at half the rate of top-line growth suggests a disciplined approach to achieving profitability, reflecting investor confidence in its financial management. Additionally, a strong performance in capital system placements, with 58 new systems installed in the recent quarter, surpassing prior guidance, further underscores the company's robust market position and growth potential in the urology sector.
Bears say
PROCEPT BioRobotics has experienced a significant decline in its stock, dropping approximately 54% year-to-date, indicating persistent challenges despite the company's ability to exceed its own guidance. Key factors contributing to the negative outlook include a potential decrease in demand for capital equipment, reduced handpiece usage by customers, heightened competitive pressure, and uncertainties surrounding reimbursement practices for Aquablation therapy. Additionally, anticipated adjustments to sales forecasts for 2026 and negative post-market performance reflect concerns over utilization rates and inventory levels.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares